IP Library › Granted Patent US 10,953,051
Granted Patent B2
US 10,953,051 · App. 16/010,106 · Granted Mar 23, 2021

Methods and means for protecting the skin against pathogenic microorganisms

Inventors: Christine Lang (Berlin, DE); Andreas Hellmann (Berlin, DE); Markus Veen (Berlin, DE); Budde Eckhard (Berlin, DE); Mewes Boettner (Berlin, DE); Andreas Reindl (Mannheim, DE); Rolf Knoll (Laudenbach, DE)
Assignee: Novozymes A/S
A61K35/747A61K9/0014A61K9/19A61P31/04A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,953,051
App. No.
16/010,106
Granted
Mar 23, 2021
Kind
B2
Abstract

Described are microorganisms which are, in a first aspect, able to to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Claims (19)

1. A method for the prophylaxis or treatment of skin against transient pathogenic micro flora, the method comprising administering to an individual in need thereof a prophylactically or therapeutically effective amount of a cosmetic or pharmaceutical composition, wherein the composition comprises a microorganism which is able to stimulate the growth of one or more microorganisms of the resident skin microbial flora and which does not stimulate the growth of microorganisms of the transient pathogenic micro flora, and wherein said microorganism is selected from a Lactobacillus paracasei having DSMZ accession number DSM 17248, a Lactobacillus brevis having DSMZ accession number DSM 17247, a Lactobacillus brevis having DSMZ accession number DSM 17250 and a Lactobacillus fermentum having DSMZ accession number DSM 17249.

2. The method of claim 1 , wherein said microorganism is able to stimulate the growth of Staphylococcus epidermidis.

3. The method of claim 2 , wherein stimulation of the growth of Staphylococcus epidermidis is measured in an in situ skin assay.

4. The method of claim 1 , wherein said microorganism does not stimulate the growth of Staphylococcus aureus.

5. The method of claim 1 , wherein said microorganism is in an inactive form.

6. The method of claim 5 , wherein in said microorganism is thermally inactivated or lyophilized.

7. The method of claim 1 , wherein the composition comprises a cosmetically acceptable carrier or excipient.

8. The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable carrier or excipient.

9. The method of claim 1 , wherein the method is the prophylaxis or treatment of dermatitis.

10. The method of claim 9 , wherein the dermatitis is atopic dermatitis, psoriasis, poison-ivy dermatitis, eczema herpeticum, kerion or scabies.

11. The method of claim 1 , wherein the individual is a human.

12. The method of claim 1 , wherein the microorganism is isolated.

13. The method of claim 1 , wherein the composition comprises the microorganism in an amount between 10 3 and 10 8 cells per mg in solid form, or between 10 2 and 10 13 cells per mL in liquid form.

14. The method of claim 1 , wherein the composition is administered topically.

15. A method of preventing or treating dermatitis, the method comprising administering to a patient in need thereof a prophylactically or therapeutically effective amount of a cosmetic or pharmaceutical composition, wherein the composition comprises an isolated microorganism selected from a Lactobacillus paracasei having DSMZ accession number DSM 17248, a Lactobacillus brevis having DSMZ accession number DSM 17247, a Lactobacillus brevis having DSMZ accession number DSM 17250 and a Lactobacillus fermentum having DSMZ accession number DSM 17249, and wherein said microorganism has the ability to stimulate the growth of at least one microorganism of the resident skin microbial flora and does not stimulate the growth of microorganisms of the transient pathogenic micro flora.

16. The method of claim 15 , wherein said microorganism is in an inactive form.

17. The method of claim 15 , wherein the composition is administered topically.

18. The method of claim 15 , wherein said microorganism is able to stimulate the growth of Staphylococcus epidermidis , and wherein said microorganism does not stimulate the growth of Staphylococcus aureus.

19. The method of claim 1 , wherein said microorganism is able to stimulate the growth of Staphylococcus epidermidis , and wherein said microorganism does not stimulate the growth of Staphylococcus aureus.

Priority Claims (1)
EP 05013494 · Jun 22, 2005 · regional
Continuity (7)
Continuation 15247001 · Aug 25, 2016
Continuation 14082881 · Nov 18, 2013
Continuation 13604124 · Sep 5, 2012
Continuation 11921497
Provisional Application 60740084 · Nov 28, 2005
Related Publication 20190381117A1 · Dec 19, 2019
Related Publication 20200121741A9 · Apr 23, 2020